Back to top

gene-editing: Archive

Zacks Equity Research

Editas (EDIT) Stock Gains 23% in the Past 6 Months: Here's Why

Editas (EDIT) shares have gained 23% in the past six months, driven by encouraging findings from the EDIT-301 studies in SCD and TDT, along with a licensing deal for its CAS9 gene-editing tool with Vertex.

VRTXPositive Net Change BLUENegative Net Change EDITNegative Net Change CRSPNegative Net Change

Zacks Equity Research

Vertex (VRTX), CRISPR Get Positive CHMP Opinion for Gene-Therapy

Vertex (VRTX) and CRISPR get a positive CHMP opinion, recommending the conditional approval of Casgevy for the treatment of SCD and TDT.

VRTXPositive Net Change BLUENegative Net Change EDITNegative Net Change CRSPNegative Net Change